Search results
Showing 16 to 30 of 30 results for abiraterone
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
data on the effectiveness of enzalutamide after previous treatment with abiraterone. Any explanatory notes(if applicable) The use of...
relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and...
Awaiting development [GID-TA11558] Expected publication date: TBC
Awaiting development [GID-TA11583] Expected publication date: TBC
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
Awaiting development [GID-TA11114] Expected publication date: TBC
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
In development [GID-TA10696] Expected publication date: TBC
for erythropoietic protoporphyria [ID927] 15 May 2023 TA721 Abiraterone for treating newly diagnosed high risk metastatic hormone-naive...
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
In development [GID-TA10779] Expected publication date: TBC
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
In development [GID-TA11252] Expected publication date: TBC
data on the effectiveness of enzalutamide after previous treatment with abiraterone. TA316/1